Interview Guidance Program (IGP) for UPSC CSE 2024, Registrations Open Click Here to know more and registration
- Recently,Sanofi Pasteur’s dengvaxia vaccine has been approved by the US Food & Drug Administration(FDA).It is the first dengue vaccine to get the regulatory nod in the US.But US FDA has said that it can be used only by those who have a previous history of the disease particularly in dengue-endemic areas
- Dengvaxia is a live,attenuated dengue virus.An attenuated virus is a virus that retains its properties of triggering an immune response in the body but its ability to lead to a disease is compromised.
- This vaccine has to be administered in people of ages 9 to 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
- Dengvaxia is the first dengue vaccine to be licensed.Mexico had been the first country to clear it in 2015.Subsequently it has been cleared in some 20 countries.
- However,Dengvaxia had also ran into trouble two years ago when the Philippines had to suspend a school vaccination programme following several casualties.
- Further,India in 2017 had said that Sanofi will be allowed to be marketed in India after it had undergone phase III clinical trials that establish safety and efficacy of a drug on Indian subjects.
- According to the Centers for Disease Control and Prevention, an estimated 400 million dengue virus infections occur around the world.India is also among the dengue-endemic countries.
- Dengue is spread through the bite of an infected female Aedes Aegypti mosquito.The mosquito becomes infected when it feeds on the blood of a person infected with the virus.After about one week,the mosquito can then transmit the virus while biting a healthy person.
Discover more from Free UPSC IAS Preparation Syllabus and Materials For Aspirants
Subscribe to get the latest posts sent to your email.